Applied Biosystems Inc.

Applied Biosystems — Applera — The Third Annual Piper Jaffray Europe Conference 2008

25 slides from Applied Biosystems's conference presentation, Jun 25, 2008

  1. Slide 1: The Third Annual Piper Jaffray Europe Conference

    Slide 1: The Third Annual Piper Jaffray Europe Conference

    Piper Jaffray June 2008 24-25, Applied Biosystems Industry expertise: Business Services - Clean technology - Consumer - Financial Institutions - Health Care - Industiral Growth - Technology The Third Annual Piper Jaffray Europe Conference

  2. Slide 2: Piper Jaffray Europe Conference

    Slide 2: Piper Jaffray Europe Conference

    Piper Jaffray Europe Conference Peter Dworkin Vice President, Investor Relations & Corp. Communications Applera Corporation June 25, 2008

  3. Slide 3: Safe Harbor Statement

    Slide 3: Safe Harbor Statement

    Piper Jaffray June 2008 3 Safe Harbor Statement Statements presented which are not historical facts, including, but not limited to, those relating to revenue growth, financial targets, product and marketing prospects, and product demand, are forward looking statements and are subject to a variety of

  4. Slide 4: Forward-looking statements

    Slide 4: Forward-looking statements

    Piper Jaffray June 2008 4 Certain statements contained in this presentations are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and Invitrogen and Applera intend that such forward-looking statements be subject to the safe harbor created there

  5. Slide 5: Non-GAAP Measurements and Additional Information

    Slide 5: Non-GAAP Measurements and Additional Information

    Piper Jaffray June 2008 5 Non-GAAP Measurements This presentation and discussion includes certain financial information which constitute “non-GAAP financial measures” as defined by the SEC. The GAAP measures which are most directly comparable to these measures, as well as a reconciliation of these m

  6. Slide 6: Applied Biosystems Company Overview/Highlights

    Slide 6: Applied Biosystems Company Overview/Highlights

    Piper Jaffray June 2008 6 Applied Biosystems Company Overview/Highlights • ABI (NYSE) is a global leader in supplying the life science industry with advanced technology; founded in 1981; ~5,000 employees; HQ in Foster City, CA, USA; FY07 revenue $2.1bn • Serving research, pharmaceutical, and applied

  7. Slide 7: Gaining Financial Momentum (Non-GAAP performance)

    Slide 7: Gaining Financial Momentum (Non-GAAP performance)

    May 2008 © 2008 Applied Biosystems 7 Gaining Financial Momentum (Non-GAAP performance) 53.3% 54.7% 15.4% 16.5% $1.06 $1.24 $1.79B $1.91B * Operating Margin and non-GAAP EPS exclude special items. GAAP reconciliations can be found at www.appliedbiosystems.com in the Financial Reports page of the Inve

  8. Slide 8: Revenue Mix

    Slide 8: Revenue Mix

    8 Piper Jaffray June 2008 Revenue Mix 43% 40% 17% 25% 42% 18% 40% Consumables Instruments Other YTD FY 08 Business Mix YTD % chg vs. prior year Instruments -1.5% Consumables 10.2% Other 9.5% Total 5.2% • 59% of YTD FY08 revenues recognized outside of the United States • Revenue reported in 5 product

  9. Slide 9: SOLiD System Advances

    Slide 9: SOLiD System Advances

    9 Piper Jaffray June 2008 SOLiDTM System Advances • SOLiD 2.0 Now Shipping – Early access customers achieving >13Gb runs – Can detect and map inserts ranging from 600bp-10Kb – More accurate and robust than SOLiD 1.0 • Delivering Key Project Performance – 1000 Genomes Project (Baylor & BGI) – Cancer

  10. Slide 10: Sequencing Continuum – Next Generation Technologies Are Expanding the Market

    Slide 10: Sequencing Continuum – Next Generation Technologies Are Expanding the Market

    10 Piper Jaffray June 2008 Research (CE) -7.2% Research (NGS) 35.1% Commercial (CE) 9.5% Source: L.E.K. Consulting and AB Internal Sequencing Continuum – Next Generation Technologies Are Expanding the Market • High volume research segments are beginning to utilize NGS technologies • CE will continue

  11. Slide 11: Building from a Strong Market Presence in Mass Spec

    Slide 11: Building from a Strong Market Presence in Mass Spec

    11 Piper Jaffray June 2008 Addressable Market Market Trends Strategy Building from a Strong Market Presence in Mass Spec Products / Markets Applications •Biomarker discovery and validation •Proteomics •Protein ID and Characterization •Drug Metabolism & ADME-Tox •Protein purification • Disease Resear

  12. Slide 12: Creating the Premier Provider of Biotechnology Reagents and Systems

    Slide 12: Creating the Premier Provider of Biotechnology Reagents and Systems

    12 Piper Jaffray June 2008 Creating the Premier Provider of Biotechnology Reagents and Systems Definitive Merger Agreement Announced June 12, 2008

  13. Slide 13: Combining Industry Leaders

    Slide 13: Combining Industry Leaders

    13 Piper Jaffray June 2008 Combining Industry Leaders • Founded: 1987 • Premier provider of consumable kits and reagents • Annual revenue of $1.3 billion • Leading positions in: – Cell Culture (GIBCO) – Labeling and Detection – Molecular Biology Kits • ~4,700 employees • 1,200 patents & licenses • C

  14. Slide 14: Transaction Overview

    Slide 14: Transaction Overview

    14 Piper Jaffray June 2008 Transaction Overview Transaction Structure Consideration and Relative Ownership Approvals Company Name Headquarters Closing • Invitrogen will acquire all of the outstanding shares of Applied Biosystems for $38 per share in a combination of cash and stock, for a total value

  15. Slide 15: Transaction Overview (Continued): Board Composition and Executive Management

    Slide 15: Transaction Overview (Continued): Board Composition and Executive Management

    15 Piper Jaffray June 2008 Board Composition Executive Management • 9 Invitrogen and 3 Applera board members Greg Lucier Chairman and CEO • Invitrogen CEO and Board Member since May 2003 • Invitrogen Chairman since April 2004 • Former Corporate Officer of General Electric Corporation David Hoffmeist

  16. Slide 16: Newco Competitive Advantages

    Slide 16: Newco Competitive Advantages

    16 Piper Jaffray June 2008 Newco Competitive Advantages New Company Well-Positioned to Benefit From Macrotrends Genomics and cell biology convergence Translation of technologies to applied markets Race to understand human genome and genetic variations Growth in emerging geographies Positioned to cap

  17. Slide 17: Strategic Rationale

    Slide 17: Strategic Rationale

    17 Piper Jaffray June 2008 • Highly complementary, best-in-class product offerings • Broad and extensive commercial network • Strong platform for expansion into high-growth markets • Significant value creation opportunities for shareholders • Strong financial profile Strategic Rationale Merger combi

  18. Slide 18: With Highly Complementary Revenue Streams

    Slide 18: With Highly Complementary Revenue Streams

    18 Piper Jaffray June 2008 ...With Highly Complementary Revenue Streams Consumables & Services* 60% Mass Spec Instruments 19% Instrument Reagent Systems 21% Consumables & Services* 74% Mass Spec Instruments 12% Instrument Reagent Systems 14% Consumables & Services* 99% Instrument Reagent Systems 1%

  19. Slide 19: Broad and Extensive Commercial Network with Complementary Skills

    Slide 19: Broad and Extensive Commercial Network with Complementary Skills

    19 Piper Jaffray June 2008 • Excels at repeat business • e-Commerce expertise • 1,000+ supply centers • Strong relationships with bench scientists • Excels at systems sales • Global service infrastructure • Presence beyond life sciences • High level customer relationships • Approximately 3,000 sales

  20. Slide 20: Strong Platform for Expansion Into High Growth Markets

    Slide 20: Strong Platform for Expansion Into High Growth Markets

    20 Piper Jaffray June 2008 Market Size Market Growth Capabilities: Applied Markets $9B Low double digits Emerging Geographies $1B Midteen’s Cell Biology $6B High single digits Next Gen Sequencing >35% $200M Strong Platform for Expansion Into High Growth Markets

  21. Slide 21: Significant Opportunities for Value Creation

    Slide 21: Significant Opportunities for Value Creation

    21 Piper Jaffray June 2008 • At least $125 million annual cost savings by 3rd year – Raw material synergies – Overhead redundancies – Facility rationalization – R&D scale • At least $50 million annual Operating Income from revenue synergies by 3rd year – Cross selling/channel synergies – Penetration

  22. Slide 22: Strong Financial Profile

    Slide 22: Strong Financial Profile

    22 Piper Jaffray June 2008 • ~$3.5 billion in combined LTM revenue • Strong EBITDA and operating cash flow contribution • Intent to quickly repay debt LTM March 31, 2008 $803 23% $480 22% $323 24% Operating Cash Flow as % of Revenue $859 25% $490 23% $369 28% EBITDA(1) as % of Revenue $3,496 $2,173

  23. Slide 23: Revenue Diversified Across Segments

    Slide 23: Revenue Diversified Across Segments

    23 Piper Jaffray June 2008 Revenue Diversified Across Segments... ...with a significant contribution from high-margin consumables Rev. By End Markets Rev. By Product Mix Industry & Other 20% Pharma & Biotech 30% Academic & Govt 50% Rev. By Geography United States 44% Europe 34% APAC 16% Other 6% Con

  24. Slide 24: Strategic Rationale

    Slide 24: Strategic Rationale

    24 Piper Jaffray June 2008 • Highly complementary, best-in-class product offerings • Broad and extensive commercial network • Strong platform for expansion into high-growth markets • Significant opportunities for value creation for shareholders • Strong financial profile Strategic Rationale Merger c

  25. Slide 25: Forward Looking Statements

    Slide 25: Forward Looking Statements

    25 Piper Jaffray June 2008 24-25, Applied Biosystems Industry Expertise: Business Services - Clean Technology - Consumer - Financial Institutions - Health Care - Industrial Growth - Technology The Third Annual Guides For the Journey - Piper Jaffray * * * FORWARD LOOKING STATEMENTS Some statements ma

Source: SEC EDGAR · DEFA14A filed Jun 25, 2008

More decks from Applied Biosystems Inc.